Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT01684852 Completed - Dry Eye Syndromes Clinical Trials

Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution

Start date: May 2012
Phase: N/A
Study type: Observational

This is a comparative, open label, parallel group, non interventional study to further demonstrate the efficacy and tolerability of BAT04. In addition the efficacy and safety shall be compared to Hyaluronic acid (HA)-Product. The patient applies BAT04 or HA-Product according to the instructions for use six times daily in both eyes over a period of 28 days. Response to treatment is recorded at day 28.

NCT ID: NCT01684436 Completed - Dry Eye Clinical Trials

Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye

Start date: October 1, 2012
Phase: Phase 4
Study type: Interventional

This study will access changes in tear protein levels and symptoms of dry eye following insertion of a punctal plug.

NCT ID: NCT01682460 Completed - Glaucoma Clinical Trials

Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients

IVES
Start date: August 2012
Phase: Phase 4
Study type: Interventional

Research indicates that many people who are being treated for glaucoma have dry eyes. The purpose of this study is to test the use of artificial tears to alleviate dryness signs and symptoms in people who are using medication to treat glaucoma. The study hypothesis is that the use of artificial tears will result in an improvement in clinical signs and symptoms associated with dry eyes.

NCT ID: NCT01679015 Completed - Clinical trials for Allergic Conjunctivitis

Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes

Start date: August 2012
Phase: N/A
Study type: Observational

Evaluating the percentage of patients that suffer from eye allergies and determining whether they also have dry eyes.

NCT ID: NCT01675570 Completed - Dry Eye Syndrome Clinical Trials

A Study of RX-10045 in the Treatment of Dry Eye Disease

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to assess the efficacy, tolerability and safety of RX-10045 Ophthalmic Solution in patients with Dry Eye Disease.

NCT ID: NCT01670357 Completed - Dry Eye Syndrome Clinical Trials

Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome

DES
Start date: April 2012
Phase: Phase 2
Study type: Interventional

This study is to determine the efficacy and safety of 3% or 5% DA-6034 eye drops compared with placebo in dry eye syndrome.

NCT ID: NCT01660256 Completed - Dry Eye Clinical Trials

Confirmatory Study of OPC-12759 Ophthalmic Solution

Start date: August 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to verify whether OPC-12759 ophthalmic solution is effective compared with placebo in dry eye patients. OPC-12759 ophthalmic suspension will be used as a reference drug.

NCT ID: NCT01657253 Completed - Dry Eye Clinical Trials

Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-148 in the ocular surface of patients with mild to moderate dry eye compared with ophthalmic solution Systane®

NCT ID: NCT01650584 Completed - Dry Eye Disease Clinical Trials

Evaluation of Ocular Comfort With ISTA Tears vs Systane

Start date: June 2012
Phase: N/A
Study type: Interventional

To assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease (DED)

NCT ID: NCT01636206 Completed - Dry Eye Disease Clinical Trials

Safety Study of Lifitegrast to Treat Dry Eye

SONATA
Start date: October 16, 2012
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.